Effects of anti-VEGF agents on rat retinal Müller glial cells.
OBJECTIVE
To evaluate the effects of an anti-rat vascular endothelial growth factor antibody (ARVA) and bevacizumab (Avastin) on rat retinal Müller glial cells (RMGCs) in vivo and in vitro.


METHODS
Rat RMGCs were identified and cultivated, and were then treated with bevacizumab (0.1, 0.25, and 1 mg/ml), ARVA (0.1, 0.5, and 1 microg/ml), or 1 mg/ml of rat immunoglobulin G (IgG) for 12, 24, 48, and 72 h. The numbers of viable RMGCs were determined using a trypan blue dye exclusion assay and a methyl thiazolyl tetrazolium colorimetric assay. In the in vivo study, the rats received intravitreal injections of 5 microl bevacizumab (3.75 mg/ml), ARVA (15 microg/ml), and rat IgG (1 mg/ml). The electroretinogram was recorded. Seven days after the injections, histopathologic changes and glial fibrillary acidic protein expression of RMGCs in the retina were analyzed by immunohistochemistry with hematoxylin-eosin and fluorescent staining.


RESULTS
After exposure to bevacizumab at various concentrations for various periods of time, the stained cell numbers and optical density values of mitochondrial dehydrogenase activity of RMGCs had no significant differences (p>0.05) from those of the control group and IgG medium. In the stained cells, ARVA demonstrated a dose-dependent increase. Compared with those treated for 12 and 24 h, the increase of stained cells treated with 0.5 and 1 microg/ml ARVA at 48 and 72 h was very significant (p<0.01). The optical densities of RMGCs exposed to 0.5 and 1 microg/ml of ARVA at 48 and 72 h were significantly lower than cells exposed to a fresh culture medium (p<0.01). The histology of both treated and control eyes after intravitreal injection was similar and showed no anatomic signs of toxicity. There were no obvious glial fibrillary acidic protein upregulations of RMGCs in all groups. The scotopic electroretinogram responses to flashes of light in the control and treated eyes had similar b-wave amplitudes.


CONCLUSIONS
Intravitreal bevacizumab and ARVA had no short-term, direct retinal toxicity in rats. Bevacizumab exerts no inhibition on rat RMGCs, while ARVA at higher doses (over 0.5 microg/ml) may be harmful to the growth of RMGCs.
Guo
Bin
B
Bayi hospital, Department of ophthalmology, Yang Gongjin, Nanjing, Jiangsu, China. greatrobin@163.com
Wang
Yingli
Y
Hui
Yannian
Y
Yang
Xinguang
X
Fan
Qinhua
Q
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D000818:Animals; D000906:Antibodies / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology / Q000633:toxicity; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002452:Cell Count; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004596:Electroretinography; D056965:Injections, Intraocular; D009457:Neuroglia / Q000166:cytology / Q000187:drug effects*; D051381:Rats; D017208:Rats, Wistar; D012160:Retina / Q000166:cytology* / Q000502:physiology; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology*; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000906:Antibodies; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab
J Neurophysiol. 1980 May;43(5):1355-66
6246222
Retina. 2006 Nov-Dec;26(9):1006-13
17151487
Invest Ophthalmol Vis Sci. 2010 Jun;51(6):3216-25
20042644
Exp Cell Res. 2004 Sep 10;299(1):68-78
15302574
Cardiovasc Hematol Agents Med Chem. 2007 Apr;5(2):147-54
17430137
Cerebrovasc Dis. 2006;21 Suppl 2:9-20
16651810
Neuroreport. 2004 Jul 19;15(10):1633-7
15232297
Trans Am Ophthalmol Soc. 2003;101:183-9; discussion 189
14971576
Retina. 2006 Mar;26(3):257-61
16508423
Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1844-52
17389520
Ophthalmol Clin North Am. 2006 Sep;19(3):335-44
16935208
Clin Exp Optom. 2005 May;88(3):132-45
15926876
Eye (Lond). 2010 Mar;24(3):497-505
20057511
Arch Ophthalmol. 2005 Apr;123(4):509-16
15824225
Rev Neurosci. 2004;15(4):293-307
15526553
J Neurochem. 2004 Oct;91(1):167-75
15379897
Retina. 2008 Jan;28(1):46-55
18185137
Clin Ophthalmol. 2008 Jun;2(2):339-46
19668725
Retina. 2009 Sep;29(8):1062-6
19734760
Brain Res. 2003 Apr 18;969(1-2):195-204
12676380
Graefes Arch Clin Exp Ophthalmol. 2009 Dec;247(12):1601-8
19597740
Prog Retin Eye Res. 2006 Jul;25(4):397-424
16839797
Invest Ophthalmol Vis Sci. 2000 Jun;41(7):1971-80
10845624
Br J Ophthalmol. 2006 Oct;90(10):1316-21
16723358
J Biol Chem. 2006 Mar 10;281(10):6625-31
16373345
Retina. 2006 Oct;26(8):882-8
17031287
Graefes Arch Clin Exp Ophthalmol. 2010 Jun;248(6):819-24
20169356
Am J Ophthalmol. 2006 Jul;142(1):162-4
16815270
Diabetes. 1998 May;47(5):815-20
9588455
Health Technol Assess. 2008 May;12(16):iii-iv, ix-201
18462575
Am J Health Syst Pharm. 2004 Nov 1;61(21 Suppl 5):S21-6
15552623
Retina. 2006 Jul-Aug;26(6 Suppl):S71-9
16832305
Graefes Arch Clin Exp Ophthalmol. 2007 Dec;245(12):1837-42
17347807
Br J Ophthalmol. 2007 Sep;91(9):1230-3
17475701